2
Orphan Designations
0 approved
5
FDA Approvals
Latest: QVAR REDIHALER (2017)
0
Active Trials
142 recruiting
4
Rare Diseases
across 10 areas
0
News (30d)
Quiet
Teva Respiratory, LLC is a company with 2 orphan drug designations across 4 rare diseases, including 5 FDA-approved therapies.
Disease-by-disease pipeline progression from orphan designation through clinical trials to FDA approval.
Source: FDA Orphan Drug Designations, ClinicalTrials.gov, Drugs@FDA
| Disease | Drug(s) | Stage |
|---|---|---|
| COVID-19–associated multisystem inflammatory syndrome in children | reslizumab | Des.TrialAppr. |
| bilirubin encephalopathy | reslizumab | Des.TrialAppr. |
| hypereosinophilic syndrome | reslizumab | Des.TrialAppr. |
| spinal muscular atrophy | reslizumab | Des.TrialAppr. |
0% of portfolio targets high unmet need diseases
5
overlap in 2+ diseases
0/4
candidate diseases
0
avg importance: 0
0
affecting portfolio
0% of portfolio targets high unmet need diseases
5
overlap in 2+ diseases
0/4
candidate diseases
0
avg importance: 0
0
affecting portfolio